person · Reporting owner

TULLMAN GLEN

Disclosed activity across 3 companies

Tapewire entity: 140602
SEC CIK: 0001213349

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Health Assurance Acquisition Corp.HAAC · Entity 122106	Director	November 12, 2020	November 12, 2020
Teladoc Health, Inc.TDOC · Entity 1547	Director	April 01, 2021	April 02, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Health Assurance Acquisition Corp.

Report date November 12, 2020 · Filed November 12, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B common stockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-11-12 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination.

Teladoc Health, Inc.

Report date April 01, 2021 · Filed April 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	275,793	Ending reported balance After 2021-04-01 transaction · row 8 8 source rows · reconciled sequence Row 1 · 2021-04-01 · Exercise / conversion · Acquired 329,863 · Balance 605,656 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. Row 2 · 2021-04-01 · Sale · Disposed 60,148 · Balance 545,508 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F2: Represents the weighted average price of transactions ranging from $182.29 to $183.28. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 8 to this Form 4. Row 3 · 2021-04-01 · Sale · Disposed 45,089 · Balance 500,419 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F3: Represents the weighted average price of transactions ranging from $183.29 to $184.28. Row 4 · 2021-04-01 · Sale · Disposed 44,825 · Balance 455,594 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F4: Represents the weighted average price of transactions ranging from $184.29 to $185.28. Row 5 · 2021-04-01 · Sale · Disposed 24,759 · Balance 430,835 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F5: Represents the weighted average price of transactions ranging from $185.30 to $186.28. Row 6 · 2021-04-01 · Sale · Disposed 38,977 · Balance 391,858 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F6: Represents the weighted average price of transactions ranging from $186.30 to $187.29. Row 7 · 2021-04-01 · Sale · Disposed 98,588 · Balance 293,270 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F7: Represents the weighted average price of transactions ranging from $187.30 to $188.29. Row 8 · 2021-04-01 · Sale · Disposed 17,477 · Balance 275,793 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F8: Represents the weighted average price of transactions ranging from $188.295 to $189.00.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.26 · Expires 2021-04-30	Direct	0	Reported balance After 2021-04-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-04-01 · Exercise / conversion · Disposed 329,863 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020. F11: The option vested in full on October 30, 2020.
Common StockSEC Table I · non-derivative	IndirectSee footnote	21,233	Reported balance Holding disclosure · report date 2021-04-01 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 21,233 F9: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,812	Reported balance Holding disclosure · report date 2021-04-01 · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · Balance 1,812 F10: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2020.

F2: Represents the weighted average price of transactions ranging from $182.29 to $183.28. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 8 to this Form 4.

F3: Represents the weighted average price of transactions ranging from $183.29 to $184.28.

F4: Represents the weighted average price of transactions ranging from $184.29 to $185.28.

F5: Represents the weighted average price of transactions ranging from $185.30 to $186.28.

F6: Represents the weighted average price of transactions ranging from $186.30 to $187.29.

F7: Represents the weighted average price of transactions ranging from $187.30 to $188.29.

F8: Represents the weighted average price of transactions ranging from $188.295 to $189.00.

F9: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F10: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F11: The option vested in full on October 30, 2020.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Livongo Health, Inc.

Report date September 11, 2020 · Filed October 30, 2020

Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2020-10-30 transaction · row 11 4 source rows · reconciled sequence Row 1 · 2020-05-05 · Gift · Disposed 19,941 · Balance 927,862 Row 7 · 2020-10-29 · Other · Acquired 37,712 · Balance 965,574 F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E. Row 9 · 2020-10-30 · Other · Acquired 27,105 · Balance 992,679 F14: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P. Row 11 · 2020-10-30 · Disposition to issuer · Disposed 992,679 · Balance 0 F16: Includes 77,652 restricted stock units ("RSUs"). F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F18: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
Common StockSEC Table I · non-derivative	IndirectSee footnote	12,080	Reported balance After 2020-09-11 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-09-11 · Other · Acquired 12,080 · Balance 12,080 F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-10-29 · Other · Disposed 1,185,097 · Balance 0 F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2020-10-29 · Other · Disposed 109,748 · Balance 0 F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2020-10-29 · Other · Disposed 176,361 · Balance 0 F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-29 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2020-10-29 · Other · Disposed 195,277 · Balance 0 F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	35,887	Reported balance After 2020-10-30 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2020-10-30 · Other · Disposed 940,788 · Balance 35,887 F12: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners. F13: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	185,121	Reported balance After 2020-10-30 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 10 · 2020-10-30 · Other · Acquired 173,041 · Balance 185,121 F15: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-30 transaction · row 12 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 12 · 2020-10-30 · Disposition to issuer · Disposed 35,887 · Balance 0 F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F13: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-10-30 transaction · row 13 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 13 · 2020-10-30 · Disposition to issuer · Disposed 185,121 · Balance 0 F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2024-02-12	Direct	0	Reported balance After 2020-10-30 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-10-30 · Disposition to issuer · Disposed 297,954 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F20: Shares subject to the option are fully vested and immediately exercisable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2025-03-09	Direct	0	Reported balance After 2020-10-30 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2020-10-30 · Disposition to issuer · Disposed 969,169 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F20: Shares subject to the option are fully vested and immediately exercisable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-04-30	Direct	0	Reported balance After 2020-10-30 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2020-10-30 · Disposition to issuer · Disposed 1,294,722 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F22: One-fourth of the shares subject to the option vested on May 1, 2018 and 1/48 of the shares vest monthly thereafter.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-01-16	Direct	0	Reported balance After 2020-10-30 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2020-10-30 · Disposition to issuer · Disposed 1,040,360 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F23: One-fourth of the shares subject to the option vested on January 17, 2019 and 1/48 of the shares vest monthly thereafter.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-06-18	Direct	0	Reported balance After 2020-10-30 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2020-10-30 · Disposition to issuer · Disposed 166,000 · Balance 0 F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F24: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP.

F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners.

F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners.

F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners.

F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners.

F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E.

F12: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners.

F13: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F14: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P.

F15: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP.

F16: Includes 77,652 restricted stock units ("RSUs").

F17: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).

F18: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).

F19: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.

F20: Shares subject to the option are fully vested and immediately exercisable.

F21: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions).

F22: One-fourth of the shares subject to the option vested on May 1, 2018 and 1/48 of the shares vest monthly thereafter.

F23: One-fourth of the shares subject to the option vested on January 17, 2019 and 1/48 of the shares vest monthly thereafter.

F24: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 25, 2020 Filed Jun 29, 2020 21:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	80,099	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017830 · doc4.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 260,358 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F8 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
June 25, 2020 Filed Jun 29, 2020 21:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	72,337	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017830 · doc4.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 235,134 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F6 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
June 25, 2020 Filed Jun 29, 2020 21:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	45,017	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017830 · doc4.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 146,324 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F4 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
June 25, 2020 Filed Jun 29, 2020 21:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	486,183	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017830 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,580,122 F1 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F2 · ownership.nature: The shares are held of record by 7wire Ventures LLC-Series EosHealth. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Ventures LLC-Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	170,000	$0.00 Strike: $0.74	$0.00	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · derivative · entry 14 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,954 Underlying: Common Stock · 170,000 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F14 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	13,175	$60.27	$794,103.36	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 8 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,932 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.15 to $61.11, inclusive. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	26,629	$59.55	$1,585,794.23	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 7 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,107 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.14 to $60.13, inclusive. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	30,109	$58.79	$1,770,087.03	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 6 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 941,736 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.12 to $59.10, inclusive. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	45,040	$57.68	$2,597,956.74	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,845 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.11 to $58.10, inclusive. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	10,093	$56.61	$571,362.71	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,016,885 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.10 to $56.97, inclusive. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	40,954	$54.48	$2,231,055.15	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,978 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.10 to $55.00, inclusive. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	4,000	$53.61	$214,453.20	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,932 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.09 to $54.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) to this Form 4. Read SEC document
May 26, 2020 Filed May 28, 2020 17:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	170,000	$0.74	$125,800.00	Disclosure SEC source: 0001209191-20-032683 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,071,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019, as amended and restated. Read SEC document
May 14, 2020 Filed May 18, 2020 18:41 UTC	Livongo Health, Inc. LVGO · Entity 145566	GrantCommon Stock	82,828	$0.00	$0.00	Disclosure SEC source: 0001209191-20-030223 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,932 F1 · shares: The reported shares are represented by restricted stock units which vest in 16 equal quarterly installments beginning on August 25, 2020. Read SEC document
May 05, 2020 Filed Oct 30, 2020 17:15 UTC	Livongo Health, Inc. LVGO · Entity 145566	GiftCommon Stock	19,941	$0.00	$0.00	Disclosure SEC source: 0001639225-20-000060 · wf-form4_160409251194751.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,862 Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	19,941	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010677 · doc4.xml · nonDerivative · entry 7 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819,104 F12 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire LP, 7wire Ventures, LLC - Series Livongo D and 7wire Ventures, LLC - Series Livongo E. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	288,469	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010677 · doc4.xml · nonDerivative · entry 6 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,673,890 F11 · kind: Represents a pro rata in-kind distribution by 7wire LP without consideration to its partners. F10 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	802,458	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010677 · doc4.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,962,359 F9 · kind: Represents the receipt of shares by 7wire LP pursuant to pro rata in-kind distributions by 7wire Ventures, LLC - Series EosHealth and 7wire Ventures LLC - Series Livongo C without consideration to its partners (including 7wire LP). F10 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	60,071	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010677 · doc4.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 340,457 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F8 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	54,247	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010677 · doc4.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 307,471 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F6 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	93,790	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010677 · doc4.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 191,341 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners (including 7wire LP). F4 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	OtherCommon Stock	1,307,682	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010677 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,066,305 F1 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners (including 7wire Ventures Fund, L.P., or 7wire LP). F2 · ownership.nature: The shares are held of record by 7wire Ventures LLC-Series EosHealth. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Ventures LLC-Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
March 17, 2020 Filed Mar 19, 2020 16:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	50,096	$0.00 Strike: $0.74	$0.00	Disclosure SEC source: 0001209191-20-020264 · doc4.xml · derivative · entry 12 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,954 Underlying: Common Stock · 50,096 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F10 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document
March 17, 2020 Filed Mar 19, 2020 16:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	119,904	$0.00 Strike: $0.36	$0.00	Disclosure SEC source: 0001209191-20-020264 · doc4.xml · derivative · entry 11 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 119,904 shares Expires 2024-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F10 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document
March 17, 2020 Filed Mar 19, 2020 16:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	54,368	$22.02	$1,196,933.27	Disclosure SEC source: 0001209191-20-020264 · doc4.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,163 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.11, inclusive. Read SEC document
March 17, 2020 Filed Mar 19, 2020 16:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	45,023	$21.20	$954,275.99	Disclosure SEC source: 0001209191-20-020264 · doc4.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,531 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.98, inclusive. Read SEC document
March 17, 2020 Filed Mar 19, 2020 16:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	70,609	$20.55	$1,451,212.66	Disclosure SEC source: 0001209191-20-020264 · doc4.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,554 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document
March 17, 2020 Filed Mar 19, 2020 16:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	50,096	$0.74	$37,071.04	Disclosure SEC source: 0001209191-20-020264 · doc4.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document
March 17, 2020 Filed Mar 19, 2020 16:18 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	119,904	$0.36	$43,165.44	Disclosure SEC source: 0001209191-20-020264 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries E Convertible Preferred Stock · Derivative	60,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 15 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · ownership.nature: The shares are held of record by 7Wire Ventures Wanxiang Strategic Fund I, LLC, or 7Wire Wanxiang. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Wanxiang. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries E Convertible Preferred Stock · Derivative	400,528	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 14 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 400,528 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries E Convertible Preferred Stock · Derivative	488,683	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 13 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 488,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries D Convertible Preferred Stock · Derivative	361,718	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 12 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 361,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries D Convertible Preferred Stock · Derivative	250,080	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 11 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 250,080 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries C Convertible Preferred Stock · Derivative	285,131	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 10 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 285,131 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries C Convertible Preferred Stock · Derivative	2,104	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 9 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionSeries A Convertible Preferred Stock · Derivative	3,506	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · derivative · entry 8 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionCommon Stock	60,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · nonDerivative · entry 5 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · ownership.nature: The shares are held of record by 7Wire Ventures Wanxiang Strategic Fund I, LLC, or 7Wire Wanxiang. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Wanxiang. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionCommon Stock	400,528	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · nonDerivative · entry 4 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 400,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionCommon Stock	361,718	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · nonDerivative · entry 3 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 361,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionCommon Stock	285,131	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · nonDerivative · entry 2 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 285,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:29 UTC	Livongo Health, Inc. LVGO · Entity 145566	ConversionCommon Stock	745,093	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-020579 · doc4.xml · nonDerivative · entry 1 TULLMAN GLEN · CIK 0001213349 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,159,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.